3149 completed, 675 unknown, 375 recruiting, 197 terminated. 2557 Not applicable, 481 Phase 2, 402 Phase 4, 284 Phase 3, 225 Phase 1.
Follow Hyperinsulinism: new trials by email Literature Review of Hyperinsulinism trials Research Report on Hyperinsulinism
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Inhibiting GABA Transaminase to Relieve Obesity Induced Hyperinsulinemia and Insulin Resistance Vigabatrin Pill, Placebo oral tablet - Hyperinsulinism, Insulin Resistance | Phase 2 | Withdrawn | University of Arizona | 2030-04-15 | 2025-07-30 | |
| The Effects of Glucagon on Hepatic Metabolism in People With Type 2 Diabetes After Caloric Restriction Caloric Restriction, Hyperglycemic clamp - Type2diabetes | Phase 2 | Not yet recruiting | Adrian Vella | 20 | 2027-12-15 | 2026-10-28 |
| Postpartum Semaglutide to Reduce Cardiometabolic Risk After Gestational Diabetes Mellitus Semaglutide (Wegovy) weekly injection - Gestational Diabetes Mellitus (GDM), Metabolic Syndrome | Phase 2 / Phase 3 | Not yet recruiting | University of Massachusetts, Worcester | 226 | 2027-09-01 | 2026-09-28 |
| cfMSC Therapy for Diabetes cfMSC therapy for diabetes - Type II Diabetes Mellitus | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 30 | 2027-06-30 | 2026-11-02 |
| Assessing Trauma-related Links Between Affective and Metabolic Systems prazosin - Posttraumatic Stress Disorder, Metabolic Syndrome | Phase 4 | Not yet recruiting | VA Office of Research and Development | 70 | 2027-03-01 | 2026-10-15 |
| Exercise and Protein to Reduce Muscle Loss During GLP-1-Based Treatment in Type 2 Diabetes Supervised exercise training, protein supplement, Standardized lifestyle counseling - Type 2 Diabetes (T2DM), Obesity & Overweight | Not applicable | Not yet recruiting | German Diabetes Center | 94 | 2027-02-01 | 2026-11-09 |
| The Simplified Total-body Resistance Exercise for Muscular Hypertrophy for Diabetic Population (D-STORM) D-STORM Resistance Training Programme, usual care - Type 2 Diabetes Mellitus (T2DM), Sarcopenia | Not applicable | Not yet recruiting | Universiti Teknologi Mara | 56 | 2027-01-01 | 2026-06-25 |
| Endoscopic Band Ligation for Type 2 Diabetes Mellitus (ENDOBAND-DM) Endoscopic Band Ligation (ENDOBAND-DM) - Type 2 Diabetes Mellitus (T2DM) | Not applicable | Not yet recruiting | El Katib Hospital | 10 | 2027-01-01 | 2026-09-10 |
| Human Models of Selective Insulin Resistance: Pancreatic Clamp Insulin human, Octreotide Acetate, Glucagon - Insulin Resistance, Hyperinsulinemia | Phase 1 | Not yet recruiting | Columbia University | 36 | 2027-01-01 | 2026-02-06 |
| Impact of Dietary Fat and Menstrual Cycle Phases in Type 1 Diabetes Low Fat Mixed Meal, High Fat Mixed Meal - Type 1 Diabetes Mellitus, Glycemic Variability | Not applicable | Not yet recruiting | Instituto de Investigacion Sanitaria La Fe | 50 | 2027-01-01 | 2026-11-09 |
| Mechanisms of Fasting-Induced Insulin Resistance 60-hour Fasting, 12-hour Overnight Fasting (control) - Insulin Resistance, Fasting-Induced Insulin Resistance | Not applicable | Not yet recruiting | German Diabetes Center | 18 | 2027-01-01 | 2026-11-10 |
| Efficacy and Safety of Semaglutide Versus Placebo on Cardiometabolic Profile in Patients With Schizophrenia With Metabolic Syndrome Semaglutide + TAU, Placebo + TAU - Schizophrenia Disorder, Metabolic Syndrome | Phase 3 | Not yet recruiting | All India Institute of Medical Sciences, Bhubaneswar | 600 | 2026-12-01 | 2026-08-18 |
| Peripheral Vascular Effects of Insulin in Obesity human insulin - Obesity (BMI>30), Insulin Resistance | Early Phase 1 | Not yet recruiting | University of Missouri-Columbia | 64 | 2026-12-01 | 2026-10-15 |
| VITAL-IMPACT: Improving Cardiometabolic Health in Black Individuals Through Therapeutic Augmentation of Cyclic Guanosine Mono-Phosphate Signaling Pathway Vericiguat 10 MG, Placebo, Insulin Sensitivity Test - Cardiovascular Diseases, Insulin Sensitivity/Resistance | Phase 2 | Not yet recruiting | University of Alabama at Birmingham | 200 | 2026-12-01 | 2026-01-23 |
| Interplay of Central and Peripheral Vascular Effects of Insulin in Obesity human insulin - Obesity (BMI>30), Insulin Resistance | Early Phase 1 | Not yet recruiting | University of Missouri-Columbia | 64 | 2026-12-01 | 2026-10-15 |
| IGOB131 As A GLP-1 Modulator For Metabolic Disorders In Adults With Obesity IGOB131, Dextrin - Obesity & Overweight | Phase 2 | Not yet recruiting | University of Yaounde 1 | 80 | 2026-12-01 | 2026-10-20 |
| Fecal Microbiota Transplantation (FMT) to Slow Biological Aging Fecal microbiota transplantation delivery through oral capsules (HBI MBiotix Caps), PLACEBO for Fecal microbiota delivery through oral capsules - Aging, Healthy, Aging and Cognitive Health | Not applicable | Not yet recruiting | Human Biome S.A. | 68 | 2026-12-01 | 2026-11-03 |
| Relacorilant in Patients With Poorly Controlled Type 2 Diabetes and Autonomous Cortisol Secretion Relacorilant - Type 2 Diabetes, Hypercortisolism | Phase 1 / Phase 2 | Not yet recruiting | The University of Texas Health Science Center at San Antonio | 34 | 2026-12-01 | 2026-11-09 |
| Alpha-Lipoic Acid Added to Dapagliflozin and Insulin Resistance in Type 2 Diabetes Alpha-Lipoic Acid (ALA), Placebo - Diabetes Mellitus, Type 2, Insulin Resistance Syndrome | Phase 3 | Not yet recruiting | Fayoum University | 70 | 2026-12-01 | 2026-11-12 |
| Trial of the Combination of Alpha-Lipoic Acid and Mirabegron in Women and in Men With Obesity Alpha-lipoic acid, Mirabegron, Placebo - Insulin Resistance, Obesity | Phase 2 | Not yet recruiting | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 60 | 2026-11-17 | 2026-11-12 |
Showing 20 of 4829. Sign in to see all of them.
Insulin Resistance (2964) · Metabolic Syndrome (2098) · Obesity (1200) · Diabetes Mellitus, Type 2 (733) · Diabetes Mellitus (653) · Overweight (320) · Motor Activity (279) · Cardiovascular Diseases (275) · Inflammation (269) · Hypertension (263) · Glucose Intolerance (208) · Prediabetic State (193) · Diabetes Mellitus, Type 1 (182) · Non-alcoholic Fatty Liver Disease (167) · Dyslipidemias (161)
Nutritional and Metabolic Diseases (4820) · Glucose Metabolism Disorders (4765) · Metabolic Diseases (4727) · Pathological Conditions, Signs and Symptoms (1923) · Insulin Resistance (1777) · Endocrine System Diseases (1724) · Signs and Symptoms (1577) · Nutrition Disorders (1429) · Body Weight (1410) · Overnutrition (1394) · Overweight (1077) · Diabetes Mellitus (878) · Pathologic Processes (544) · Behavior (472)
Exercise (211) · Metformin (192) · Insulin (165) · Diet (68) · Pioglitazone (63) · Insulin Glargine (55) · Cholecalciferol (42) · Rosiglitazone (37) · Sodium Chloride (36) · High-Intensity Interval Training (35) · Insulin Lispro (35) · Glucose (34) · Insulin Aspart (33) · Glucose Tolerance Test (30) · Caloric Restriction (29)
University of Aarhus (57) · Massachusetts General Hospital (54) · Maastricht University Medical Center (52) · University of Copenhagen (51) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (44) · Pennington Biomedical Research Center (39) · Stanford University (38) · Cairo University (35) · Laval University (33) · Washington University School of Medicine (33) · Mayo Clinic (31) · University of Colorado, Denver (31) · University of Alabama at Birmingham (29) · University of Toronto (29) · University of California, San Francisco (27)
United States (1614) · Canada (298) · Denmark (216) · China (171) · Italy (168) · Germany (165) · United Kingdom (161) · Spain (143) · Netherlands (142) · France (141) · Taiwan (102) · Turkey (Türkiye) (94) · Mexico (91) · South Korea (90) · Egypt (81)
Joshua R Cook, MD, PhD (10) · Kazuoki Kondo, MD (10) · Michael Roden, Prof., MD (10) · Samuel Klein, MD (10) · Steven J Russell, MD, PhD (10) · David JA Jenkins, MD, PhD, DSc (8) · John L Sievenpiper, MD, PhD (7) · Russell J de Souza, ScD, RD (7) · Tracey McLaughlin, MD (7) · Bruno Geloneze, MD, PhD (6) · Jack A Yanovski, M.D. (6)
PMID 37526194, PMID 33512717, PMID 31004409, PMID 10480510, PMID 18820647, PMID 24191286, PMID 25527677, PMID 27524654, PMID 32449201, PMID 33210751, PMID 37595266, PMID 37735841, PMID 10205010, PMID 11289482, PMID 12485966, PMID 14688154, PMID 15572438, PMID 16183552, PMID 16338915, PMID 16636217, PMID 16775236, PMID 17245174, PMID 17443373, PMID 17666313, PMID 18175740, PMID 18305915, PMID 18557952, PMID 19125756, PMID 19475464, PMID 19723613, PMID 19805654, PMID 19889232, PMID 20024643, PMID 20208057, PMID 20826632, PMID 21070531, PMID 21668975, PMID 21694556, PMID 21737826, PMID 21781358, PMID 21865361, PMID 22090467, PMID 22311420, PMID 22719806, PMID 22773702, PMID 22990269, PMID 23052794, PMID 23633524, PMID 24205974, PMID 24212451
2019 (8), 2005 (7), 2008 (6), 2014 (5), 2009 (4), 2015 (4), 2016 (4), 2017 (4), 2025 (4), R01DK077966 (4), 2018 (3), 2023 (3), K12DK133995 (3), K23DK140614 (3), P20GM109096 (3)